The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•26 February 2026•

1 min read

argenx Announces Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis

Key Facts

1The Phase 3 ADAPT OCULUS trial met its primary endpoint evaluating VYVGART in adults with ocular myasthenia gravis (oMG).

2Results showed statistically significant improvement (p-value = 0.012) in the Myasthenia Impairment Index (MGII) compared to placebo.

Biotechnology firm argenx SE announced successful topline results from its Phase 3 ADAPT OCULUS trial, evaluating the efficacy of VYVGART in adults with ocular myasthenia gravis (oMG). The study met its primary endpoint, demonstrating a statistically significant improvement in the Myasthenia Impairment Index (MGII) compared to placebo, with a p-value of 0.012. Following these positive outcomes, argenx plans to submit a Supplemental Biologics License Application (sBLA) to the U.S. FDA to expand the drug's clinical label. This regulatory move is expected to broaden the market reach of VYVGART and drive future revenue growth. Analysts view the successful trial as a major de-risking event for the company, likely boosting investor confidence. The expansion of the drug's approved use supports higher valuation projections for the biotech leader.